ASX:4DXHealthcare Services
Assessing 4DMedical (ASX:4DX) Valuation After CE Mark Approval And A$83 Million Equity Raise
Why the CE Mark and equity raise matter for 4DMedical
The trigger for 4DMedical (ASX:4DX) is the CE Mark approval for its CT:VQ imaging technology, which opens commercial use across the European Union and highlights a new phase for the company’s respiratory imaging ambitions.
This certification arrives alongside an A$83.0 million follow-on equity offering at A$5.90 per share, suggesting 4DMedical is pairing European market access with fresh capital to support CT:VQ deployment and broader...